Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Long-Term Deferred Tax (2016 - 2025)

Historic Long-Term Deferred Tax for Regen BioPharma (RGBPP) over the last 12 years, with Q3 2025 value amounting to $4.6 million.

  • Regen BioPharma's Long-Term Deferred Tax rose 624.23% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 624.23%. This contributed to the annual value of $4.6 million for FY2025, which is 624.23% up from last year.
  • Latest data reveals that Regen BioPharma reported Long-Term Deferred Tax of $4.6 million as of Q3 2025, which was up 624.23% from $4.3 million recorded in Q3 2024.
  • Regen BioPharma's 5-year Long-Term Deferred Tax high stood at $4.6 million for Q3 2025, and its period low was $4.1 million during Q3 2023.
  • In the last 5 years, Regen BioPharma's Long-Term Deferred Tax had a median value of $4.4 million in 2021 and averaged $4.4 million.
  • As far as peak fluctuations go, Regen BioPharma's Long-Term Deferred Tax skyrocketed by 2606.0% in 2021, and later plummeted by 553.21% in 2023.
  • Quarter analysis of 5 years shows Regen BioPharma's Long-Term Deferred Tax stood at $4.4 million in 2021, then changed by 0.0% to $4.4 million in 2022, then dropped by 5.53% to $4.1 million in 2023, then rose by 3.38% to $4.3 million in 2024, then increased by 6.24% to $4.6 million in 2025.
  • Its Long-Term Deferred Tax was $4.6 million in Q3 2025, compared to $4.3 million in Q3 2024 and $4.1 million in Q3 2023.